Cargando...
2452. Treatment and Outcomes of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
BACKGROUND: Daptomycin (dap) is approved as an alternative to vancomycin (van) for therapy of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI). Cases of therapy failure associated with the emergence of daptomycin-nonsusceptible (DNS) MRSA strains have been documented. I...
Gardado en:
| Publicado en: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6255085/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.2105 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|